risperidone has been researched along with Neurodevelopmental Disorders in 5 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 7.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| "In children and adolescents treated with risperidone, hyperprolactinemia is a frequent complication that may have clinical repercussions." | 3.81 | Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects. ( Celeri, EH; Dalgalarrondo, P; de Mello, MP; Della Torre, OH; dos Santos Júnior, A; Ferreira Neto, AP; Fontana, TS; Guerra Júnior, G; Henriques, TB; Paes, LA; Sewaybricker, LE, 2015) |
| " The use of antipsychotics is associated with a number of adverse effects for which routine monitoring is recommended." | 1.48 | Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada. ( Cepoiu-Martin, M; Chen, W; Cooke, L; Duncan, D; Pringsheim, T; Stang, A; Symonds, C, 2018) |
| "Risperidone-treated children and adolescents were assessed for CHRNA7 copy number state using droplet digital PCR and genomic quantitative PCR." | 1.46 | CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents. ( Calarge, CA; Gillentine, MA; Grochowski, CM; Lupski, JR; Schaaf, CP; White, JJ, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scarborough, J | 1 |
| Mueller, F | 1 |
| Arban, R | 1 |
| Dorner-Ciossek, C | 1 |
| Weber-Stadlbauer, U | 1 |
| Rosenbrock, H | 1 |
| Meyer, U | 1 |
| Richetto, J | 1 |
| Dhindsa, RS | 1 |
| Zoghbi, AW | 1 |
| Krizay, DK | 1 |
| Vasavda, C | 1 |
| Goldstein, DB | 1 |
| Gillentine, MA | 1 |
| White, JJ | 1 |
| Grochowski, CM | 1 |
| Lupski, JR | 1 |
| Schaaf, CP | 1 |
| Calarge, CA | 1 |
| Chen, W | 1 |
| Cepoiu-Martin, M | 1 |
| Stang, A | 1 |
| Duncan, D | 1 |
| Symonds, C | 1 |
| Cooke, L | 1 |
| Pringsheim, T | 1 |
| dos Santos Júnior, A | 1 |
| Henriques, TB | 1 |
| de Mello, MP | 1 |
| Ferreira Neto, AP | 1 |
| Paes, LA | 1 |
| Della Torre, OH | 1 |
| Sewaybricker, LE | 1 |
| Fontana, TS | 1 |
| Celeri, EH | 1 |
| Guerra Júnior, G | 1 |
| Dalgalarrondo, P | 1 |
5 other studies available for risperidone and Neurodevelopmental Disorders
| Article | Year |
|---|---|
Preclinical validation of the micropipette-guided drug administration (MDA) method in the maternal immune activation model of neurodevelopmental disorders.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Mice; Neurodevelopmental Disorders; Pharmaceuti | 2020 |
A Transcriptome-Based Drug Discovery Paradigm for Neurodevelopmental Disorders.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents; Antipsycho | 2021 |
CHRNA7 Deletions are Enriched in Risperidone-Treated Children and Adolescents.
Topics: Adolescent; alpha7 Nicotinic Acetylcholine Receptor; Antipsychotic Agents; Child; Cohort Studies; Fe | 2017 |
Antipsychotic Prescribing and Safety Monitoring Practices in Children and Youth: A Population-Based Study in Alberta, Canada.
Topics: Adolescent; Alberta; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chi | 2018 |
Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects.
Topics: Adolescent; Alleles; Antipsychotic Agents; Child; Cross-Sectional Studies; Female; Genetic Predispos | 2015 |